Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-9083402B-BCDD-41AB-AA01-6AFA9318ADD4_5_en-US
DOI: https://doi.org/10.31003/USPNF_M18280_05_01
DOI Ref: g9s9q



# Clindamycin Phosphate



$C_{18}H_{34}ClN_2O_8PS$ 504.96

L-*threo*-α-D-*galacto*-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-, 2-(dihydrogen phosphate), (2*S*-*trans*)-;
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-*trans*-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-*threo*-α-D-*galacto*-octopyranoside 2-(dihydrogen phosphate) CAS RN®: 24729-96-2; UNII: EH6D7113I8.

## DEFINITION

Clindamycin Phosphate has a potency equivalent to NLT 758 µg/mg of clindamycin ($C_{18}H_{33}ClN_2O_5S$), calculated on the anhydrous basis.

## IDENTIFICATION

***Change to read:***

• **A.** ▲**Spectroscopic Identification Tests** ⟨197⟩, *Infrared Spectroscopy*: **197K**▲ (CN 1-May-2020)

**Standard:** Add 0.2 mL of water to 50 mg of USP Clindamycin Phosphate RS, and heat to dissolve. Evaporate to dryness under vacuum, and dry the residue at 100°–105° for 2 h.

**Sample:** Add 0.2 mL of water to 50 mg of Clindamycin Phosphate, and heat to dissolve. Evaporate to dryness under vacuum, and dry the residue at 100°–105° for 2 h.

**Acceptance criteria:** Meets the requirements

• **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

## ASSAY

• **Procedure**

**Solution A:** Add 14 mL of phosphoric acid to 4000 mL of water. Add 10 mL of ammonium hydroxide, and adjust with ammonium hydroxide to a pH of 5.6 ± 0.1.

**Solution B:** Acetonitrile and methanol (900:100)

**Solution C:** *Solution B* and *Solution A* (80:920)

**Solution D:** *Solution B* and *Solution A* (480:520)

**Diluent:** *Solution B* and *Solution A* (20:80)

**Mobile phase:** See *Table 1*.

**Table 1**

| Time (min) | Solution C (%) | Solution D (%) |
|---|---|---|
| 0 | 95 | 5 |
| 40 | 5 | 95 |
| 41 | 95 | 5 |
| 46 | 95 | 5 |

**System suitability solution:** 2.2 mg/mL of USP Clindamycin Phosphate System Suitability RS in *Diluent*. Shake, and sonicate to dissolve.

**Standard solution:** 2.2 mg/mL of USP Clindamycin Phosphate RS in *Diluent*. Shake, and sonicate to dissolve.

**Sample solution:** 2.2 mg/mL of Clindamycin Phosphate in *Diluent*. Shake, and sonicate to dissolve.

**Chromatographic system**

(See *Chromatography ⟨621⟩, System Suitability*.)

**Mode:** LC

**Detector:** UV 214 nm

**Column:** 4.6-mm × 25-cm; 5-µm packing L7

**Column temperature:** 40°

**Flow rate:** 1.2 mL/min

**Injection volume:** 20 µL

**System suitability**

**Samples:** *System suitability solution* and *Standard solution*

**Suitability requirements**

**Resolution:** NLT 3.0 between clindamycin phosphate and 7-epiclindamycin phosphate, *System suitability solution*

**Tailing factor:** NMT 2.0 for clindamycin phosphate, *Standard solution*

**Relative standard deviation:** NMT 0.73%, *Standard solution*

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the quantity of clindamycin ($C_{18}H_{33}ClN_2O_5S$), in µg/mg, in the portion of Clindamycin Phosphate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P$$

$r_U$ = peak response from the *Sample solution*

$r_S$ = peak response from the *Standard solution*

$C_S$ = concentration of USP Clindamycin Phosphate RS in the *Standard solution* (mg/mL)

$C_U$ = concentration of Clindamycin Phosphate in the *Sample solution* (mg/mL)

$P$ = potency of clindamycin in USP Clindamycin Phosphate RS (µg/mg)

**Acceptance criteria:** NLT 758 µg/mg on the anhydrous basis

## IMPURITIES

• **Organic Impurities**

**Solution A, Solution B, Solution C, Solution D, Diluent, Mobile phase, System suitability solution, Sample solution,** and **Chromatographic system:** Proceed as directed in the *Assay*.

**Standard solution:** 14 µg/mL of USP Clindamycin Phosphate RS in *Diluent*. Shake, and sonicate to dissolve.

**System suitability**

**Samples:** *System suitability solution* and *Standard solution*

**Suitability requirements**

**Resolution:** NLT 3.0 between 7-epiclindamycin phosphate and clindamycin phosphate, *System suitability solution*

**Tailing factor:** NMT 2.0 for clindamycin phosphate, *Standard solution*

**Relative standard deviation:** NMT 5.0% for clindamycin phosphate, *Standard solution*

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Clindamycin Phosphate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times (F_1/F_2) \times 100$$

$r_U$ = peak response of each impurity from the *Sample solution*

$r_S$ = peak response of clindamycin phosphate from the *Standard solution*

$C_S$ = concentration of USP Clindamycin Phosphate RS in the *Standard solution* (mg/mL)

$C_U$ = concentration of Clindamycin Phosphate, corrected for water content, in the *Sample solution* (mg/mL)

$P$ = potency of clindamycin in USP Clindamycin Phosphate RS (µg/mg)

$F_1$ = conversion factor, 0.001 mg/µg

$F_2$ = relative response factor (see *Table 2*)

**Acceptance criteria:** See *Table 2*. The reporting level is 0.05%.

**Table 2**

| Name | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|---|---|---|---|
| Lincomycin phosphate[a] | 0.36 | 1.0 | 1.0 |
| Lincomycin[b] | 0.50 | 2.0 | 0.5 |
| Clindamycin B phosphate[c] | 0.77 | 1.0 | 1.5 |
| 7-Epiclindamycin phosphate[d] | 0.89 | 1.0 | 0.8 |
| Clindamycin 3-phosphate[e] | 0.93 | 1.0 | 0.3 |
| Clindamycin phosphate | 1.0 | — | — |
| Clindamycin[f] | 1.4 | 1.0 | 0.5 |
| Any individual, unspecified impurity | — | 1.0 | 1.0 |
| Total impurities | — | — | 4.0 |

[a] Methyl 6,8-dideoxy-6-[(2*S*,4*R*)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-D-*erythro*-α-D-*galacto*-octopyranoside 2-phosphate.

[b] Methyl 6,8-dideoxy-6-[(2*S*,4*R*)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-D-*erythro*-α-D-*galacto*-octopyranoside.

[c] Methyl 7-chloro-6,7,8-trideoxy-6-[(2*S*,4*R*)-1-methyl-4-ethylpyrrolidine-2-carboxamido]-1-thio-L-*threo*-α-D-*galacto*-octopyranoside 2-phosphate.

[d] Methyl 7-chloro-6,7,8-trideoxy-6-[(2*S*,4*R*)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-D-*erythro*-α-D-*galacto*-octopyranoside 2-phosphate.

[e] Methyl 7-chloro-6,7,8-trideoxy-6-[(2*S*,4*R*)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-L-*threo*-α-D-*galacto*-octopyranoside 3-phosphate.

[f] Methyl 7-chloro-6,7,8-trideoxy-6-[(2*S*,4*R*)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-L-*threo*-α-D-*galacto*-octopyranoside.

**SPECIFIC TESTS**

- **Crystallinity ⟨695⟩:** Meets the requirements
- **pH ⟨791⟩**

  **Sample solution:** 10 mg/mL

  **Acceptance criteria:** 3.5–4.5
- **Water Determination ⟨921⟩, *Method I*:** NMT 6.0%
- **Sterility Tests ⟨71⟩**

  **Sample solution:** 6 g of specimen aseptically dissolved in 200 mL of *Fluid A*

  **Analysis:** Test as directed in the *Test for Sterility of the Product to Be Examined, Membrane Filtration*.

  **Acceptance criteria:** It meets the requirements where the label states that it is sterile or must be subjected to further processing during the preparation of injectable dosage forms.
- **Bacterial Endotoxins Test ⟨85⟩:** It contains NMT 0.58 USP Endotoxin Units/mg of clindamycin, where the label states that Clindamycin Phosphate is sterile or must be subjected to further processing during the preparation of injectable dosage forms.

**ADDITIONAL REQUIREMENTS**

- **Packaging and Storage:** Preserve in tight containers, and store below 30°.
- **Labeling:** Where it is intended for use in preparing injectable dosage forms, the label states that it is sterile or must be subjected to further processing during the preparation of injectable dosage forms.
- **USP Reference Standards ⟨11⟩**

  USP Clindamycin Phosphate RS

  USP Clindamycin Phosphate System Suitability RS

Contains clindamycin phosphate and the following impurity:

7-Epiclindamycin phosphate;
Methyl 7-chloro-6,7,8-trideoxy-6-[(2*S*,4*R*)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-D-*erythro*-α-D-*galacto*-octopyranoside 2-phosphate.
$C_{18}H_{34}ClN_2O_8PS$ 504.96

**Auxiliary Information** - Please check for your question in the FAQs before contacting USP.

| Topic/Question | Contact | Expert Committee |
|---|---|---|
| CLINDAMYCIN PHOSPHATE | Documentary Standards Support | SM12020 Small Molecules 1 |
| REFERENCE STANDARD SUPPORT | RS Technical Services<br>RSTECH@usp.org | SM12020 Small Molecules 1 |

**Chromatographic Database Information:** Chromatographic Database

**Most Recently Appeared In:**
Pharmacopeial Forum: Volume No. PF 44(3)

**Current DocID: GUID-9083402B-BCDD-41AB-AA01-6AFA9318ADD4_5_en-US**

**DOI: https://doi.org/10.31003/USPNF_M18280_05_01**

**DOI ref: g9s9q**